Table 3 Bivariable analysis

Age in years

18–29

78 (25.6)

24 (30.8%)

54 (69.2%)

1

30–39

130 (42.8)

47 (36.2%)

83 (63.8%)

0.92 (0.76–1.12)

≥ 40

96 (31.6)

31 (32.3%)

65 (67.7%)

0.98 (0.80–1.20)

Sex

Female

189 (62.2)

70 (37.0%)

119 (63.0%)

1

Male

115 (37.8)

32 (27.8%)

83 (72.2%)

1.15 (0.98–1.34)

Participant address

Kampala

198 (65.1)

66 (33.3%)

132 (66.7%)

1

Wakiso

81 (26.7)

28 (34.6%)

53 (65.4%)

0.98 (0.81–1.18)

Others

25 (8.2)

8 (32%)

17 (68%)

1.02 (0.77–1.36)

Marital status (n = 268)

Married

140 (52.2)

47 (33.6%)

93 (66.4%)

1

Unmarried

128 (47.8)

42 (32.8%)

86 (67.2%)

1.01 (0.85–1.20)

Treatment line

First line

255 (83.9)

87 (34.1%)

168 (65.9%)

1

 s line

49 (16.1)

15 (30.6%)

34 (69.4%)

1.05 (0.86–1.29)

WHO clinical stage at time of VL non-suppression (n = 253)

Stage 1

241(95.2)

78 (32.4%)

163 (67.6%)

1

Stage 2

6(2.4)

2 (33.3%)

4 (66.7%)

0.99 (0.56–1.75)

Stage 3

3(1.2)

2 (66.7%)

1 (33.3%)

0.49 (0.10–2.46)

Stage 4

3(1.2)

1 (33.3%)

2 (66.7%)

0.99 (0.44–2.21)

Number of IAC sessions provided

> 3 Sessions

207(68.1)

82 (39.6%)

125 (60.4%)

1

3 Sessions

97(31.9)

20 (20.6%)

77 (79.4%)

1.31 (1.13–1.53)

Duration on ART at VL non-suppression (n = 302)

< 1 year

62(20.5)

24 (38.7%)

38 (61.3%)

1

> 1 to 5 years

93(30.8)

34 (36.6%)

59 (63.4%)

1.04 (0.81–1.33)

> 5 years

147(48.7)

43 (29.3%)

104 (70.7%)

1.15 (0.92–1.44)

Time to IAC linkage

≤ 1 month

153(50.3)

50 (32.7%)

103 (67.3%)

1

> 1 month- 2 month

88(29)

31 (35.2%)

57 (64.8%)

0.96 (0.80–1.16)

> 2 months

63(20.7)

21 (33.3%)

42 (66.7%)

0.99 (0.81–1.22)

Baseline non-suppressed viral load test result  (Copies/ml)

≥ 10,000

137(45.0)

66 (48.2%)

71 (51.8%)

1

5,000–10,000

34(11.2)

14 (41.2%)

20 (58.8%)

1.10 (0.80–1.52)

1,000–4,999

133(43.8)

22 (16.5%)

111 (83.5%)

1.52 (1.27–1.81)

ART regimen at time of VL non-suppression

EFV Based regimen

134(44.1)

57 (42.5%)

77 (57.5%)

1

NVP Based regimen

59(19.4)

28 (47.5%)

31 (52.5%)

0.91 (0.69–1.21)

ATV/r Based regimen

35(11.5)

8 (22.9%)

27 (77.1%)

1.34 (1.06–1.69)

DTG Based regimen

59(19.4)

2 (3.4%)

57 (96.6%)

1.68 (1.44–1.96)

LPV/r Based regimen

17(5.6)

7 (41.2%)

10 (58.8%)

1.02 (0.67–1.56)